A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.

被引：14
|
作者：
Tamberi, Stefano
Grassi, Elisa
Corbelli, Jody
Papiani, Giorgio
Barbera, Maria Aurelia
Zingaretti, Chiara
Moretti, Chiara Carli
Montroni, Isacco
Petracci, Elisabetta
Caruso, Dora
Nosseir, Sofia
Nanni, Oriana
Frassineti, Giovanni Luca
Di Bartolomeo, Maria
Marzola, Marina
Bonetti, Andrea
Gelsomino, Fabio
Pinto, Carmine
Tassinari, Davide
Ugolini, Giampaolo
机构：
[1] Ospedale Gli Infermi, Faenza, Italy
[2] Infermi Hosp, Faenza, Italy
[3] IRCCS, IRST Meldola, Unita Biostat & Sperimentazioni Clin, Ravenna, Italy
[4] Infermi Hosp, Faenza, Italy
[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biostat & Clin Trials, Meldola, Italy
[6] Ravenna Hosp, Dept Pathol, Ravenna, Italy
[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Meldola, Italy
[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Med Oncol Unit, Meldola, Italy
[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[10] Univ Ferrara, Ferrara, Italy
[11] Mater Salutis Hosp, Dept Med Oncol, Legnago, Italy
[12] Univ Hosp Modena, Modena, Italy
[13] AUSL IRCCS Reggio Emilia, Med Oncol Unit, Clin Canc Ctr, Reggio Emilia, Italy
[14] Dept Oncol, Rimini, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3607
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR plus ) breast cancer
    Khong, Hung T.
    Goodridge, Dawn N.
    Khakpour, Nazanin
    Lee, M. Catherine
    Laronga, Christine
    Armaghani, Avan J.
    Soyano-Muller, Aixa E.
    Han, Hyo
    Soliman, Hatem
    Costa, Ricardo
    Loftus, Loretta
    Hoover, Susan J.
    Kiluk, John V.
    Jameel, Zena
    Czerniecki, Brian J.
    CANCER RESEARCH, 2021, 81 (04)
  • [42] A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer.
    Duffy, Austin G.
    Makarova-Rusher, Oxana V.
    Pratt, Drew
    Kleiner, David E.
    Alewine, Christine
    Fioravanti, Suzanne
    Walker, Melissa
    Carey, Stephanie
    Figg, William Douglas
    Steinberg, Seth M.
    Anderson, Victoria
    Levy, Elliot
    Krishnasamy, Venkatesh
    Wood, Bradford J.
    Jones, Jennifer
    Citrin, Deborah E.
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer.
    Dunst, J
    Reese, T
    Debus, J
    Hoelscher, T
    Budach, W
    Rudat, V
    Wulf, J
    Mose, S
    Hinke, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 259S - 259S
  • [44] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [45] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [46] A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer
    Woodward, Wendy A.
    Fang, Penny
    Arriaga, Lisa
    Gao, Hui
    Cohen, Evan N.
    Reuben, James M.
    Valero, Vicente
    Le-Petross, Huong
    Middleton, Lavinia P.
    Babiera, Gildy V.
    Strom, Eric A.
    Tereffe, Welela
    Hoffman, Karen
    Smith, Benjamin D.
    Buchholz, Thomas A.
    Perkins, George H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (04): : 777 - 783
  • [47] A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE
    Powles, Thomas
    Galsky, Matt D.
    Castellano, Daniel
    Van Der Heijden, Michiel Simon
    Petrylak, Daniel Peter
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [49] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [50] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
    Reardon, David
    Kaley, Thomas
    Dietrich, Jorg
    Clarke, Jennifer
    Dunn, Gavin
    Lim, Michael
    Cloughesy, Tim
    Gan, Hui
    Park, Andrew
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary
    Ryan, Aileen
    Venhaus, Ralph
    NEURO-ONCOLOGY, 2018, 20 : 10 - 10
12345